Dear Bernie: Catalyst CEO McEnany defends his $375,000 price tag on an old drug once offered for free
Now that Catalyst has taken center stage as this quarter’s most frequently pilloried price gouger, the company $CPRX is trying to take a stand in defense of the $375,000 annual price tag it has slapped on its newly approved drug Firdapse.
Just ahead of his newly announced second run for the presidency, Vermont Senator Bernie Sanders called out Catalyst for “fleecing” taxpayers, the “immoral exploitation of patients” and highlighted the issue as yet another example of a drug company’s “corporate greed.” And some patients have complained bitterly that they couldn’t afford the drug now, once handed out for free to many of the people who suffer from the rare autoimmune disease Lambert-Eaton myasthenic syndrome, or LEMS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
